Pharmaceutical compositions and use in the manufacture of a medicament for the treatment of EGFRi-induced skin toxicity

By regulating HaCa-T cell activity through a combination of chlorogenic acid, ferulic acid, and zinc acetate, the skin toxicity caused by EGFRIs was resolved, achieving a highly effective treatment for skin toxicity and significantly improving skin symptoms and patients' quality of life.

CN119792343BActive Publication Date: 2026-07-21JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE
Filing Date
2025-02-18
Publication Date
2026-07-21

AI Technical Summary

Technical Problem

Existing technologies are not very effective in treating skin toxicity caused by epidermal growth factor receptor inhibitors (EGFRIs), and long-term use can lead to side effects. They cannot effectively relieve problems such as papulopustular rashes, dry and itchy skin, desquamation, periungual inflammation, and abnormal hair regeneration.

Method used

A combination of chlorogenic acid, ferulic acid, and zinc acetate was used to reverse the inhibitory effect of EGFRIs on the skin by regulating HaCa-T cell activity. The specific ratio of chlorogenic acid to ferulic acid was 1.5:1, and the total amount of chlorogenic acid to zinc acetate was 3:1. This product was used for topical drug treatment.

Benefits of technology

It significantly improved the efficacy of treating skin toxicity caused by EGFRIs, reaching 66.67%, reduced HaCa-T cell apoptosis, improved skin toxicity symptoms, restored skin function, and improved patients' quality of life.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119792343B_ABST
    Figure CN119792343B_ABST
Patent Text Reader

Abstract

The present application relates to a kind of pharmaceutical composition and its application in the preparation of EGFRIs caused by skin toxicity treatment drug, the pharmaceutical composition includes chlorogenic acid, ferulic acid and zinc salt, wherein, the mass ratio of the chlorogenic acid and the ferulic acid is 4:1~1:4, the total amount of the chlorogenic acid and the ferulic acid and the mass ratio of the zinc salt are 4:1~1:4.The pharmaceutical composition of the present application has the characteristics of curative effect and easy industrialization.
Need to check novelty before this filing date? Find Prior Art